We report a case of disseminated sporotrichosis in a 49-yearold man who was treated with multiple immunosuppressants, including tumor necrosis factor (TNF)-a antagonists (etanercept and infliximab), for presumed inflammation arthritis. This case illustrates the potential for infectious complications related to the use of cytotoxic immunosuppressants and anticytokine agents, such as TNF-a antagonists.
apy was started for what was interpreted as worsening psoriatic arthritis.
In late October, the patient developed left-side forearm edema, olecranon bursitis, and tenosynovitis. He underwent aspiration of the olecranon bursa, which also showed neutrophilic inflammation, but culture of aspirate fluid was sterile. The patient was treated with prednisone (10 mg q.d.). In November and December, the pain and swelling of the hands and wrists worsened; the patient developed nodular lesions on his arms and left leg, and therapy was started with etanercept, a TNF receptor linked to the Fc portion of human IgG1 (Enbrel; Immunex). The patient's condition showed no improvement, and the diagnosis of rheumatoid arthritis was considered, because the results of testing for rheumatoid factor were weakly positive (titer of 1:4). He was scheduled to undergo a skin biopsy of his nodular lesions but missed his appointment.
In January 2001, the patient began to receive leflunomide (Arava; Aventis), a disease-modifying antirheumatoid drug thought to prevent the expansion of activated lymphocytes, and subsequently he was treated with infliximab, an anti-TNF-a antibody (Remicade; Centocor). His hand and arm lesions began to ulcerate, and, in late January 2001, he was admitted to an outside hospital for further evaluation and treatment. Discussion. Sporotrichosis (historically known as Beurmann's disease or Schenck's disease) [1, 2] is caused by S. schenckii, a dimorphic fungus commonly found in soil, plants, or decaying plant matter, and classically is associated with exposure to rose thorns. Exposure is generally believed to occur via direct inoculation with the organism. Various clinical syndromes have been associated with S. schenckii infection, including cutaneous sporotrichosis, extracutaneous sporotrichosis (osteoarticular, pulmonary, ocular, sinus, kidney, testes, and epididymis infection, as well as meningitis), and multifocal extracutaneous (disseminated) sporotrichosis [3, 4] . Disseminated sporotrichosis is rare in immunocompetent hosts, but it can occur in individuals with underlying immunosuppression. Although disseminated sporotrichosis has been most described most widely in patients with AIDS [5] , there are scattered reports of the disease in patients with other immunosuppressive conditions, such as malignancies, solid-organ transplants, and chronic liver disease.
Studies of host immune responses to invasive fungal infections, including S. schenckii infection, have suggested an important role for innate humoral and cell-mediated immunity [6] . In mouse models of S. schenckii infection, TNF appears to play an important role in immunological control [7] [8] [9] , suggesting a mechanism by which TNF-a antagonists might predispose a person to infection by S. schenckii and lead to disseminated sporotrichosis.
To our knowledge, this is the first case of disseminated sporotrichosis related to treatment with TNF-a antagonists (in this case, etanercept and infliximab). We hypothesize that, in this patient, alcohol use, extensive exposure to rose bushes, and progressive immunosuppression (including treatment with prednisone, disease-modifying antirheumatic drugs [methotrexate and leflunomide], and TNF-a antagonists) prescribed for (misdiagnosed) arthritis resulted in progressive sporotrichosis.
Treatment with TNF-a antagonists has been associated with serious fungal, mycobacterial, and bacterial infections. Warris and colleagues [10] recently reported a case of invasive pulmonary aspergillosis associated with infliximab therapy in a 25-year-old man with Crohn disease complicated by fistulas. In response, Keenan et al. [11] reported that 6 cases of aspergillosis, 5 cases of Pneumocystis carinii pneumonia, 3 cases of histoplasmosis, 1 case of coccidioidomycosis in a septic joint, 3 cases of systemic Candida infection, and 5 cases of systemic unspecified fungal infections occurred in patients receiving infliximab since that drug was approved by the US Food and Drug Administration (FDA) in 1998. It was noted that, in almost all of these cases, there was concurrent immunosuppression, including therapy with corticosteroids, azathioprine, methotrexate, or mercaptopurine. In addition, Keane et al. [12] reported 70 cases of tuberculosis associated with infliximab treatment, and Wagner et al. [13] reported 1 case of gastrointestinal tuberculosis misdiagnosed as Crohn disease that was exacerbated by infliximab treatment. There have also been reports of bacterial infections, including listeriosis [14] and fatal pneumococcal sepsis [15] , associated with use of anti-TNF-a agents. Finally, an FDA surveillance report on etanercept published in 1999 [16] documented that 30 of the estimated 25,000 patients treated with etanercept developed serious infections, including sepsis, and that 6 of these patients died. In addition, a controlled study of etanercept treatment for sepsis showed a higher incidence of death among patients treated with etanercept than among patients treated with placebo [17] .
We believe this case illustrates some important points. (1) It is obviously important to make the correct diagnosis prior to initiating potentially life-threatening immunosuppressive therapy. (2) We need an increasing appreciation of the potential for infectious complications related to the use of TNF-a antagonists. (3) Immunosuppressive regimens that contain both cytotoxic and anticytokine agents may make individuals more prone to infectious complications than either of these classes of agents would if used alone. We suggest that this newly recognized entity-namely, a severe or disseminated infection in a patient receiving cytotoxic and anticytokine agentsmight be aptly referred to as "cytotoxic anticytokine infection syndrome."
